

**DCAT**  
**TOP** ↑  
**Industry**  
**NEWS**

***BUSY WEEK?** Here are the  
TOP INDUSTRY NEWS stories  
you might have missed, as  
selected by DCAT Editorial  
Director Patricia Van Arnum.*

**1. Teva Plans Major Manufacturing and Job Cuts**

Teva Pharmaceutical Industry announced plans for a major restructuring involving staff reductions of 7,000 employees and the closing or divesting of 15 manufacturing plants following disappointing second-quarter results in which the company took a goodwill impairment charge of \$6.1 billion related to the performance of its US generics business. [Read More](#)

**2. Merck & Co. Updates Impact on Mfg from Network Cyberattack**

As part of its second-quarter earnings report, Merck & Co. provided an update on the impact on its operations resulting from a June 27, 2017 network cyberattack that led to a disruption of its worldwide operations, including manufacturing, research, and sales operations. [Read More](#)

**3. Seattle Genetics Purchases Manufacturing Facility from BMS**

Seattle Genetics, a Bothell, Washington-headquartered biotechnology company specializing in antibody drug conjugates, has agreed to purchase Bristol-Myers Squibb's pharmaceutical manufacturing facility in Bothell. Seattle Genetics plans to use the facility for antibody production for current and future pipeline programs. [Read More](#)

**4. Baxter Acquires Claris Injectables for \$625 Million**

Baxter International has completed its previously announced \$625-million acquisition of Claris Injectables, a generic injectables pharmaceutical company based in Ahmedabad, India. With this acquisition, Baxter gains a product portfolio and pipeline as well as three manufacturing plants in Ahmedabad. [Read More](#)

**5. Teva, Amgen, Allergan Advance Biosimilars to Roche's Herceptin**

In two separate moves, Teva Pharmaceutical Industries, Celltrion, a life-sciences company, Amgen, and Allergan have advanced their respective filings for biosimilar candidates to Roche's cancer drug, Herceptin, a top-selling drug for Roche with 2016 sales of CHF 6.78 billion (\$7.04 billion). [Read More](#)

**6. Astellas Plans to Wind Down ADC Research**

As part of a move to refine its oncology strategy by expanding its investment in new technologies and modalities and reducing its focus on antibody drug conjugate research, Astellas Pharma plans to wind down its Agensys research operations in Santa Monica, California. [Read More](#)

**7. J&J, Bavarian Nordic in Vaccine Deal Worth Up to \$880 Million**

Janssen Pharmaceuticals, part of Johnson & Johnson, has entered into an exclusive license and collaboration agreement with Bavarian Nordic, a Kvistgaard, Denmark-based biotechnology company, for potential new vaccine regimens against the hepatitis B virus and HIV, in a deal worth up to nearly \$880 million. [Read More](#)

**8. Evotec to Acquire Aptuit for \$300 Million**

Evotec, a Hamburg, Germany-based drug discovery and development company, has agreed to acquire Aptuit, a Greenwich, Connecticut-based pharmaceutical services company, for \$300 million. Aptuit

offers preclinical testing as well as drug-substance and drug-product manufacturing. [Read More](#)

## 9. [Daiichi Sankyo in \\$300-Million Settlement for Hypertensive Drug](#)

Daiichi Sankyo has agreed to settle for \$300 million almost 2,300 pending liability lawsuits relating to its olmesartan products (Benicar, Benicar HCT, Azor and Tribenzor), used to treat antihypertension, on claims that the products caused gastrointestinal issues. [Read More](#)

## 10. [EMA Provides Business Continuity Plan Post Brexit](#)

The European Medicines Agency (EMA) has developed and initiated a business continuity plan to deal with the uncertainty and workload implications linked to the UK's withdrawal from the European Union and the agency's relocation from London. [Read More](#)

***The DCAT organization is happy to provide this service to its members each Friday.  
Have a great weekend!***

### **About Top Industry News**

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691  
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599

[www.dcat.org](http://www.dcat.org)

Drug, Chemical, & Associated Technologies Association, One Union Street,  
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by [dcatnews@dcat.org](mailto:dcatnews@dcat.org)